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INTRODUCTION: A high proportion of patients with metastatic prostate cancer
(mPC) have bone metastases (BM) which are associated with a high level of mor-
bidity, including bone pain and skeletal related events. Although the epidemiology
of prostate cancer is well documented in the United Kingdom, data on the stage at
diagnosis, survival of metastatic cancer and data on incidence / prevalence of BM
subsequent to prostate cancer are surprisingly scarce for such a common disease.
OBJECTIVES: To develop a disease model to estimate the number of men with BM
due to PC in the UK from 2010 to 2020. METHODS: A four-stage disease model
(non-mPC,mPC, death from PC, death-other causes), simulating the progression of
PC was developed to estimate the incidence and prevalence of mPC and BM in the
United Kingdom. The incidence-based model was run over 50 years to obtain inci-
dence and prevalence data. A 1-year cycle length was used. Inputs were obtained
from published official sources. Validation used UK national statistics on number
of cases / deaths with PC. After validation, a BM-component was fitted within the
PC model to ensure consistency with the UK national statistics and obtain esti-
mates of the future incidence and prevalence of BM in the United Kingdom.
RESULTS: The model estimated an increase in new patients with PC from 2006 to
2020 from 35,510 to 47,417.mPC patientswill increase from20,000 (1990) to 66,100
(2020). Assuming a 30% prevalence of BM and a RR of 1.35 for survival with BM
compared to visceral metastases, the number of PC diagnosed men living with BM
ranges from 6,000 (1995) to 16,200 (2020). CONCLUSIONS: This disease model
shows that the prevalence of PC is expected to increase in the UK. A substantial
number of patients with mPC will develop BM though this is expected to be stable.
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INTRODUCTION: Approximately 65-75% of patients with metastatic breast cancer
(mBC) suffer from bone metastases (BM). Complications include pain, impaired
mobility, hypercalcemia and pathologic fractures, affecting quality of life and prog-
nosis. The epidemiology of breast cancer is well documented. Data on the inci-
dence and prevalence of BM subsequent to breast cancer are scarce. OBJECTIVES:
To develop a diseasemodel to estimate the number of womenwith BC and BM due
to BC in the United Kingdom from 2010 to 2020.METHODS:A four-stage incidence-
based disease model (non-mBC, mBC, death from BC, death-other causes), simu-
lating the progression of BC was developed to estimate the incidence and preva-
lence ofmBC and BM in the UK. It was run over 50 years using a 1-year cycle length.
Inputs were obtained from published sources. Validation used UK national statis-
tics on number of cases / deaths with BC. After validation, a BM-component was
fitted within the BCmodel to ensure consistency with UK national statistics and to
obtain estimates of the future incidence and prevalence of BM from BC in the
UnitedKingdom.RESULTS:Newcases of BC in theUnitedKingdomare predicted to
reach 53,500 in 2020. Deaths due to BC are expected to decrease from 15,750 to
11,300 deaths in 2020. Cases of mBC will likely remain stable at 25,500 cases.
Assuming a 54% prevalence of BM in mBC, a RR of 1.42 for survival with-BM versus
other-BM, the number of women with BM is assumed to remain stable at 14,000.
CONCLUSIONS: Thismodel provides new data for BMs in BC. Predictions are in line
with expectations from official sources. The model shows that a substantial num-
ber of women with BC will develop BM. Because of the large female population
living with mBC, a significant opportunity remains to improve outcomes in pa-
tients with BM.
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OBJECTIVES: Experimental and clinical data support a role for estrogens in the
development and growth of breast cancer, and lowered estrogen exposure reduces
breast cancer recurrence and new diagnoses in high-risk women. There is varied
evidence that increased physical activity is associated with breast cancer risk re-
duction in both pre- and postmenopausal women, perhaps via lowered estrogen
levels. The purpose of this study was to assess whether exercise intervention in
premenopausal women at increased breast cancer risk reduces estrogen or proges-
terone levels. METHODS: Seven healthy premenopausal women at high risk for
breast cancer completed a seven-menstrual-cycle study. The study beganwith two
pre-intervention cycles of baseline measurement of hormone levels via daily first-
morning urine collection, allowing calculation of average area-under-the-curve
(AUC) hormone exposure across the menstrual cycle. Participants then began 5
cycles of exercise training to maintenance of 300 minutes per week at 80-85% of
maximal aerobic capacity. During the last two exercise cycles, urinary estradiol
and progesterone levels were again measured daily. RESULTS: Total estrogen ex-
posure declined by 18.9% and total progesterone exposure by 23.7%. Declines were
mostly due to decreased luteal phase levels, though menstrual cycle and luteal
phase lengths were unchanged. CONCLUSIONS: The study demonstrated the fea-
sibility of daily urine samples and AUCmeasurement to assess hormone exposure
in experimental studies of the impact of interventions on ovarian hormones. The
results suggest value in exercise interventions to reduce hormone levels in high-
risk women with few side effects and potential for incremental benefits to surgical
or pharmacologic interventions.
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OBJECTIVES: This study evaluated rates of treatment modifications and reasons
for these changes among patients treated with angiogenesis inhibitors in Irish
clinical practice. METHODS: Data from medical records were retrospectively re-
viewed at 3 large oncology centers in Ireland for mRCC patients who were 18
years and received sunitinib (N54), sorafenib (N9), bevacizumab (N6), or tem-
sirolimus (N7) as first-line treatment from January 1, 2005 to August 31, 2010.
Proportions of patients with treatment discontinuation, interruption, or dose
change, and reasons formodifications and time tomodifications were determined.
RESULTS: Due to small sample sizes in other groups, only results for sunitinib are
summarized. Patients totaling 1.9% had prior cytokine therapy. Median first-line
angiogenesis inhibitor treatment duration for sunitinib was 8.7 months. A total of
87% of patients treated with first-line sunitinib experienced1 adverse event (AE);
18.5% experienced 1 grade 3/4 AE. 70.4% of patients discontinued first-line
sunitinib mainly due to progressive disease (38.9%). AEs were the main reason for
treatment interruption among 20 (37%) patients that had an interruption. A total of
94.4% of patients started treatment on 50 mg QD 4/2 dosing; 33.3% of them were
dose reduced to 37.5mg QD 4/2 withmedian time to reduction 2.7months. Overall,
77.8% of the patients had 1 treatment modification. Adverse events led to treat-
ment modifications in 42.6% of patients. Among patients who discontinued treat-
ment, 31.6% discontinued within 18 weeks (15.8% within 0-6 weeks, 7.9% in 7-12
weeks, and 7.9% in 13-18 weeks). Among patients who discontinued treatment
within 18 weeks, 66.7% discontinued due to AEs. CONCLUSIONS: Over three-quar-
ters of sunitinib patients experienced treatmentmodifications, more than half due
to AEs. About 24% of treatment discontinuations occurred within the first 2 cycles.
This real-world practice study suggests that treatment tolerability is a challenge for
physicians in the clinical care of mRCC patients.
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OBJECTIVES: Trastuzumab is a recently approved monoclonal antibody for the
treatment of HER2 positive women with metastatic breast cancer (MBC). It shows
less toxicity than cytotoxic chemotherapy. The objective of this review was to
assess the safety profile of trastuzumab monotherapy in the treatment of HER2
positive women with MBC.METHODS: A comprehensive search was conducted in
the Cochrane Library, EMBASE and PUBMED to identify randomised controlled
trials (RCTs) and single-arm studies assessing the safety of trastuzumab, as mono-
therapy, in adult HER2 positive women with MBC. The searches were conducted
from the database start to January 2011. Only English language studies were in-
cluded. Eligibility of trials was assessed by two blinded reviewers with any discrep-
ancy resolved by a third independent reviewer. Adverse events were the outcome
of interest. RESULTS: A total of 518 citations were retrieved of which five studies
met the inclusion criteria. This constituted a total of 2229 patients. Safety data
showed that gastrointestinal adverse effects (6.68%) were most frequent fol-
lowed by decrease in left ventricular ejection fraction (LVEF) (6.59%), infection
(3.86%), pain (3.14%), headache (2.87%), chills (2.33%), congestive heart failure
(1.93%), cough (1.84%), fatigue (1.44%), dyspnoea (1.21%) and pyrexia (0.76%).
CONCLUSIONS: Results show a higher incidence of gastric and cardiac adverse
events compared to other adverse events. Long term studies are required to eval-
uate risks that may be associated with trastuzumab.
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OBJECTIVES: To determine whether the issuance of a new or revised Black Box
Warning (BBW) for an Adverse Drug Reaction (ADR) by US Food and Drug Admin-
istration (FDA) increases the proportional reporting of the ADR to the FDA’s Ad-
verse Event Reporting System (AERS). METHODS: We compiled a list of Multiple
Myeloma (MM) drugs with BBWs issued after the drug approval: melphalan, tha-
lidomide, vincristine, carmustine, and doxorubicin. We searched the AERS data-
base for MM drugs and ADRs listed in BBWs and retrieved all cases. We calculated
the empiric bayes geometric mean (EBGM) values and clinical outcomes (chi-
square analyses) for each drug and ADR combination and compared them before
and after the issuance of the BBW. RESULTS: EBGM signals increased for 8 of 10
BBW drug/events: melphalan/leukemia (12.83 to 15.97); melphalan/chromosomal
aberrations (0 to 18.677); melaphalan/bone marrow suppression (5.926 to 7.629);
thalidomide/venous thrombosis (1.201 to 2.464); intrathecal vincristine/death
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